News

Microbot Medical has announced the issuance of a new U.S. patent for its modular robotic surgical system.

The U.S. Patent and Trademark Office granted the patent for a robotic system that includes a base unit and multiple tool-receiver components. These components are designed as separate modules that can be independently attached to or removed from the base.

Based in Hingham, Massachusetts, Microbot stated in a press release that the newly granted patent is a significant step forward. It could allow the company to adapt its Liberty robotic surgical system for a broader range of endovascular procedures—potentially expanding its total addressable market. The patent also strengthens Microbot’s U.S. intellectual property portfolio for Liberty, bringing its total to 12 granted patents worldwide and 57 pending applications.

The company believes this patent supports further innovation and allows for greater customization to meet varying clinical demands. This, in turn, could help Microbot reach new indications and attract a wider customer base.

Liberty was developed to make endovascular interventional procedures more accessible. According to Microbot, it is the world’s first single-use, fully disposable robotic system designed for such procedures. The company submitted the Liberty system to the FDA in December 2024.

Microbot anticipates launching Liberty in the third quarter of 2025 and is continuing its engagement with the FDA as it seeks 510(k) clearance. While this represents a slight delay from its original second-quarter expectations, the company said the review remains within the FDA’s expected timeline and should not impact its planned launch once clearance is granted.

Source: Microbot